NEW YORK, May 23 – Genomics stocks, many of which hit new lows at the end of March or beginning of April, appear to be gaining momentum, pulled higher by the market's overall rise and renewed investor confidence following the Internet crash, analysts said Wednesday.

“Total stock is up,” said Winton Gibbons, a analyst at William Blair of Chicago. But he noted that people are also separating genome stocks out from the negative association with Internet stocks.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.